American Century Companies Inc. Has $809,000 Position in Relay Therapeutics, Inc. $RLAY

American Century Companies Inc. boosted its stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) by 13.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 308,752 shares of the company’s stock after buying an additional 36,586 shares during the quarter. American Century Companies Inc. owned approximately 0.18% of Relay Therapeutics worth $809,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of RLAY. Tang Capital Management LLC lifted its stake in shares of Relay Therapeutics by 126.1% in the 4th quarter. Tang Capital Management LLC now owns 8,068,058 shares of the company’s stock valued at $33,240,000 after purchasing an additional 4,500,000 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Relay Therapeutics by 69.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,964,997 shares of the company’s stock valued at $12,216,000 after purchasing an additional 1,216,334 shares during the period. Millennium Management LLC lifted its stake in shares of Relay Therapeutics by 142.4% in the 4th quarter. Millennium Management LLC now owns 2,568,384 shares of the company’s stock valued at $10,582,000 after purchasing an additional 1,508,777 shares during the period. MPM Bioimpact LLC lifted its stake in shares of Relay Therapeutics by 11.6% in the 4th quarter. MPM Bioimpact LLC now owns 2,268,825 shares of the company’s stock valued at $9,348,000 after purchasing an additional 235,784 shares during the period. Finally, Point72 Asset Management L.P. lifted its stake in shares of Relay Therapeutics by 18.0% in the 4th quarter. Point72 Asset Management L.P. now owns 1,592,753 shares of the company’s stock valued at $6,562,000 after purchasing an additional 243,353 shares during the period. 96.98% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Relay Therapeutics

In related news, insider Peter Rahmer sold 15,724 shares of the stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $3.68, for a total transaction of $57,864.32. Following the completion of the sale, the insider directly owned 377,998 shares of the company’s stock, valued at approximately $1,391,032.64. This trade represents a 3.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Donald A. Bergstrom sold 26,701 shares of the stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $3.68, for a total value of $98,259.68. Following the sale, the insider directly owned 552,720 shares of the company’s stock, valued at $2,034,009.60. The trade was a 4.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 149,226 shares of company stock valued at $542,926 in the last ninety days. Insiders own 4.87% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Raymond James Financial dropped their price objective on Relay Therapeutics from $29.00 to $19.00 and set a “strong-buy” rating on the stock in a research note on Friday, August 8th. HC Wainwright dropped their price objective on Relay Therapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, August 26th. Finally, Guggenheim assumed coverage on Relay Therapeutics in a research note on Thursday. They issued a “buy” rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.50.

Relay Therapeutics Trading Down 2.7%

Shares of RLAY opened at $4.00 on Friday. The company has a market capitalization of $689.64 million, a price-to-earnings ratio of -2.05 and a beta of 1.60. The stock has a 50 day moving average of $3.57 and a 200 day moving average of $3.25. Relay Therapeutics, Inc. has a 12 month low of $1.77 and a 12 month high of $10.72.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.08. The business had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $0.07 million. As a group, equities research analysts predict that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current year.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.